PEG Hydrogel Capture Peptides for Amyloid Trapping
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Alzheimer's disease lack effective compositions for delivering peptide ligands that can interact with β-amyloid peptides to reduce their toxicity in the cellular environment, which is crucial for halting the progression of the disease.
Innovation Solution
A composition comprising a poly(ethylene glycol) hydrogel with bound capture peptides, such as native, retro, or retro-inverso forms of FNNGNLFIL, LPFFD, RGTWEGKW, and QSHYRHISPAQV, which are administered subcutaneously, intradermally, or transdermally to trap β-amyloid peptides, preventing their aggregation and toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If peptide ligands are administered to interact with β-amyloid peptides, then toxicity is reduced, but delivery effectiveness is insufficient
Solution Approach 1:
The patent introduces a delivery vehicle (liposome, nanoparticle, or hydrogel) as an intermediary carrier to transport peptide ligands across the blood-brain barrier. This mediator solves the delivery problem by protecting peptides from degradation and facilitating their transport into the brain, where they can then effectively interact with β-amyloid peptides to reduce toxicity.
Solution Approach 2:
The patent combines peptide ligands with delivery vehicle materials (lipids, polymers, or hydrogels) to create composite therapeutic compositions. This composite approach allows the beneficial properties of both components: the peptide's specificity for β-amyloid and the delivery vehicle's ability to cross the blood-brain barrier and protect the peptide.
2Quantity of substance
If capture peptides are bound to hydrogel for peripheral trapping, then β-amyloid concentration in brain is reduced, but composition complexity increases
Solution Approach 1:
The patent extracts and traps β-amyloid peptides from the peripheral circulation using capture peptides bound to hydrogel or solid supports. By removing β-amyloid from the bloodstream before it can cross the blood-brain barrier, the system reduces brain concentration without requiring complex active transport mechanisms.
Solution Approach 2:
The capture peptide-hydrogel system provides self-service by passively trapping β-amyloid peptides through affinity binding as they pass through the peripheral circulation. The system automatically sequesters toxic peptides without requiring external control or complex regulatory mechanisms.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The AMYTRAP system effectively binds and traps β-amyloid peptides in the peripheral circulation, preventing them from crossing the blood-brain barrier, thereby reducing their concentration in the brain and halting plaque formation, offering a therapeutic approach to manage Alzheimer's disease.
Implementation Method 1
a poly(ethylene glycol) hydrogel having bound thereto a capture peptide for a β-amyloid peptide
Implementation Method 2
a poly(ethylene glycol) hydrogel having bound thereto a capture peptide
Implementation Method 3
Peptides that are partially homologous to the central hydrophobic region of Aβ (residues 17-21), but that contain amino acids that prevent the adoption of Aβ-sheet structure bind to Aβ and inhibit amyloid formation in vitro and disaggregate preformed Aβ fibrils
Data Source
AI summary
Disclosed herein is a composition for the treatment and/or prevention of Alzheimer's disease and the delivery thereof. The composition comprises a PEG hydrogel having bound thereto a capture peptide, wherein the capture peptide is capable of binding beta-amyloid. In another embodiment, the capture peptide is attached to a solid support.